AMRN logo

AMRN
Amarin Corp - ADR

30,491
Mkt Cap
$289.89M
Volume
51.00
52W High
$20.90
52W Low
$9.44
PE Ratio
-7.40
AMRN Fundamentals
Price
$13.93
Prev Close
$14.31
Open
$14.31
50D MA
$14.80
Beta
1.02
Avg. Volume
67,680.29
EPS (Annual)
-$1.87
P/B
0.63
Rev/Employee
$2.68M
$7.15
Loading...
Loading...
News
all
press releases
AbbVie's TrenibotE Receives FDA CRL Due to Manufacturing Issues
ABBV gets FDA CRL for TrenibotE tied to manufacturing issues. The company plans a full response in the coming months.
Zacks·4d ago
News Placeholder
More News
News Placeholder
Has Amarin (AMRN) Outpaced Other Medical Stocks This Year?
Here is how Amarin (AMRN) and BioAge Labs, Inc. (BIOA) have performed compared to their sector so far this year.
Zacks·5d ago
News Placeholder
AMRX Announces Kashiv BioSciences Buyout, Solid Q1 Preliminary Results
Amneal's deal to buy Kashiv for up to $1.10B aids biosimilar push. The company posts strong preliminary Q1 results and raises 2026 EPS guidance.
Zacks·5d ago
News Placeholder
MRK Down as Triplet Therapy Fails to Meet Goal in Kidney Cancer Study
Merck stock slides as Keytruda-based triplet therapy misses main goals in a late-stage study in first-line advanced renal cell carcinoma.
Zacks·6d ago
News Placeholder
Amarin (AMRN) Q2 2025 Earnings Transcript
@media (max-width: 768px) { .image-container { width: 100% !important; float: none !important; margin: 0 0 1rem 0 !important; } } Image source: The Mo...
Nasdaq News: Markets·7d ago
News Placeholder
MRK's sBLAs for Keytruda Combo in Bladder Cancer Get FDA Priority Tag
FDA grants priority review to Merck's sBLAs for Keytruda & Keytruda SC in combination with Pfizer's Padcev in cisplatin-eligible MIBC patients.
Zacks·7d ago
News Placeholder
BIIB Inks Deal to Acquire Rights to Felzartamab in China, Stock Up
Biogen gains after securing Greater China rights to felzartamab, giving it worldwide control as phase III studies advance in immune diseases.
Zacks·7d ago
News Placeholder
Merck to Boost Oncology Pipeline With $6.7B Terns Buyout, Stock Up
MRK's $6.7B Terns buyout is set to add a promising leukemia drug candidate, boosting its oncology pipeline as it prepares for Keytruda's patent cliff.
Zacks·1mo ago
News Placeholder
Amarin (NASDAQ:AMRN) Shares Pass Above 200-Day Moving Average - Should You Sell?
Amarin (NASDAQ:AMRN) Stock Price Passes Above 200-Day Moving Average - What's Next...
MarketBeat·1mo ago
News Placeholder
Amarin (NASDAQ:AMRN) Stock Rating Upgraded by Zacks Research
Zacks Research raised Amarin from a "strong sell" rating to a "hold" rating in a report on Wednesday...
MarketBeat·2mo ago
<
1
2
...
>

Latest AMRN News

View
Top Discussions

Advertisement|Remove ads.

Advertisement|Remove ads.